Identification and characterization of 20 novel pathogenic variants in 60 unrelated Indian patients with mucopolysaccharidoses type I and type II

Autor: Prajnya Ranganath, A.S. Babu, Katta M. Girisha, Ratna Dua Puri, Shubha R. Phadke, J. Md Nurul Jain, Sheela Nampoothiri, Mohandas Nair, A.Q. Hasan, Kanishk Prasad, Kalpana Gowrishankar, Seema Kapoor, V.H. Sankar, Sumita Danda, Shagun Aggarwal, Kausik Mandal, Anusha Uttarilli, Ashwin Dalal, I. C. Verma, Meenakshi Bhat, Divya Matta
Rok vydání: 2016
Předmět:
Zdroj: Clinical Genetics. 90:496-508
ISSN: 0009-9163
DOI: 10.1111/cge.12795
Popis: Mucopolysaccharidoses (MPS), a subgroup of lysosomal storage disorders, are caused due to deficiency of specific lysosomal enzyme involved in catabolism of glycosaminoglycans. To date more than 200 pathogenic variants in the alpha-l-iduronidase (IDUA) for MPS I and ∼500 pathogenic variants in the iduronate-2-sulphatase (IDS) for MPS II have been reported worldwide. The mutation spectrum of MPS type I and MPS type II disorders in Indian population is not characterized yet. In this study, we carried out clinical, biochemical, molecular and in silico analyses to establish the mutation spectrum of MPS I and MPS II in the Indian population. We conducted molecular analysis for 60 MPS-affected patients [MPS I (n = 30) (Hurler syndrome = 17, Hurler-Scheie syndrome = 13), and MPS II (n = 30) (severe = 18, attenuated = 12)] and identified a total of 44 [MPS I (n = 22) and MPS II (n = 22)] different pathogenic variants comprising missense, nonsense, frameshift, gross deletions and splice site variants. A total of 20 [MPS I (n = 14), and MPS II (n = 6)] novel pathogenic sequence variants were identified in our patient cohort. We found that 32% of pathogenic variants detected in IDUA were recurrent and 25% in MPS II. This is the first study revealing the mutation spectrum of MPS I and MPS II patients in the Indian population.
Databáze: OpenAIRE
Externí odkaz: